

**IX BIOPHARMA LTD.**  
(Company Registration No. 200405621W)  
(Incorporated in the Republic of Singapore)

---

**PROPOSED RENOUNCEABLE NON-UNDERWRITTEN RIGHTS CUM WARRANTS ISSUE**

**- NOTICE FROM UNDERTAKING SHAREHOLDER ANSON PROPERTIES PTE. LTD.**

---

*Unless otherwise defined, all capitalised terms herein shall have the same meanings as in the Company's announcements dated 6 June 2024, 11 June 2024, 18 June 2024, 26 June 2024 and 1 July 2024 in relation to the Rights cum Warrants Issue (the "**Earlier Announcements**") and the Offer Information Statement dated 26 June 2024. Any reference to the time of day herein shall be a reference to Singapore time.*

The board of directors (the "**Board**" or "**Directors**") of iX Biopharma Ltd. (the "**Company**") refers to the Earlier Announcements and the Offer Information Statement in relation to the Rights cum Warrants Issue undertaken by the Company.

The Board wishes to update that it has been notified by Anson Properties Pte. Ltd. ("**Anson Properties**"), one of the Undertaking Shareholders, that it is unable to subscribe for its entire pro-rata entitlement of 14,684,566 Undertaking Rights Shares by 5.30 p.m. on 15 July 2024, being the last time and date for acceptance and payment for the Rights Shares under the Rights cum Warrants Issue, due to the timing of funds availability.

Anson Properties informed the Board that it remains committed to invest in the Company when its funds are available in four to six weeks' time, subject to agreement with the Company on the terms of such investment. Anson Properties is a substantial shareholder of the Company and has supported the Company in its past fund raising activities, including participating in previous two rights issues and a placement.

Due to the above, the net proceeds raised from the Rights cum Warrants Issue under the Minimum Subscription Scenario will be reduced to \$1.55 million. The Undertaking Shareholders (excluding Anson Properties) will collectively subscribe for an aggregate of 58,255,768 Undertaking Rights Shares which constitutes approximately 33.81% of the total number of Rights Shares under the Maximum Subscription Scenario. Given that there is no minimum amount that must be raised from the Rights cum Warrants Issue, the non-subscription by Anson Properties for its pro-rata entitlement is not expected to have a material adverse operational nor financial impact on the Group.

The Company will make further announcements via SGXNET as and when there are any material developments in relation to the foregoing matter.

**IX BIOPHARMA LTD.**  
**BY ORDER OF THE BOARD**

Eddy Lee Yip Hang  
Chairman & CEO

15 July 2024

---

This announcement has been reviewed by the Company's Sponsor, UOB Kay Hian Private Limited (the "**Sponsor**").

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 8 Anthony Road, #01-01, Singapore 229957, telephone: (65) 6590 6881.